Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin.
Photodynamic therapy (PDT) is used to treat malignant and nonmalignant diseases. It is also used for cosmetological skin treatment. PDT is generally considered to have a low risk of carcinogenicity. However, instances of nonmalignant human tumors turning malignant have been linked to PDT. In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA). Of these drugs, ALA and PP(Arg)(2) were found the most efficient. PDT reduced the number of papillomas, but with increasing effectiveness of the drugs, the risk of malignant transformation of the papillomas into squamous cell carcinomas increased. The underlying mechanisms are not clear and further investigations are needed.
Kwitniewski
Mateusz
M
Department of Molecular Microbiology and Serology, National Salmonella Centre, Medical University of Gdansk, Gdansk, Poland. kwitniewski@amg.gda.pl
Jankowski
Dawid
D
Jaskiewicz
Kazimierz
K
Dziadziuszko
Halina
H
Juzeniene
Asta
A
Moan
Johan
J
Ma
Li-Wei
LW
Peksa
Rafal
R
Kunikowska
Danuta
D
Graczyk
Alfreda
A
Kwasny
Miroslaw
M
Kaliszewski
Miron
M
Glosnicka
Renata
R
D015127:9,10-Dimethyl-1,2-benzanthracene; D000622:Aminolevulinic Acid / Q000627:therapeutic use*; D000818:Animals; D002273:Carcinogens; D002294:Carcinoma, Squamous Cell / Q000209:etiology*; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D053208:Kaplan-Meier Estimate; D051379:Mice; D008815:Mice, Inbred Strains; D010212:Papilloma / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011524:Protoporphyrins / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D013755:Tetradecanoylphorbol Acetate
D002273:Carcinogens; D017319:Photosensitizing Agents; D011524:Protoporphyrins; D015127:9,10-Dimethyl-1,2-benzanthracene; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX; D013755:Tetradecanoylphorbol Acetate